| Abstract |
Chronic rhinosinusitis with nasal polyps (CRSwNP) represents a significant burden on the healthcare system. Xian et al. discussed several aspects of our economic model, based on French pricing, that may impact the cost-effectiveness of biologics . Briefly, they outlined the regional disparities in the cost of biologics, the potential better outcomes of biologics in real-world evidence, and the recurrence rate after endoscopic sinus surgery (ESS). We think that these aspects may be further discussed. |
